The Scientist November 2019

Cell therapy, especially adoptive T-cell transfer, is an active area of cancer research and treatment. Although promising, many challenges from

efficacy to safety remain.

Horizon Discovery harnesses various gene-modulation technologies, such as CRISPR, rAAV, ZFN, siRNA, and shRNA, to successfully engineer

primary cells and cancer cell lines. Whole-genome pooled and targeted arrayed functional genomic screens are performed that extend to

primary human T cells. Such screens could be used to identify new targets that improve CAR-T cell survival in the immunosuppressive tumor

microenvironment, increase migration and infiltration, or reduce immunogenicity. Potential targets identified from these screens may be validated

with follow-up in vitro or in vivo studies. In this webinar, sponsored by Sartorius, current data from primary immune cells will illustrate how CRISPR–

Cas9 and RNAi can extend the use of adoptive T-cell transfer in the clinic.

VERENA BRUCKLACHER-WALDERT,PhD

Principal Scientist

Horizon Discovery Ltd.

TUESDAY, OCTOBER 29

10:30 AM - 12:00 PM EASTERN TIME

WATCH NOW!

http://www.the-scientist.com/gene-modulation-tech-sartorius

TOPICS TO BE COVERED:

• Overview of gene-modulation technologies and
  functional genomic screens


• Areas in which CRISPR-Cas9 and RNAi could be
  used to extend the use of adoptive T-cell transfer in
  the clinic

WEBINAR SPONSORED BY:

ONDEMAND

Genomic Analysis:

Steering Clinical Trials

ONDEMAND

Gene-Modulation Technologies in the Development

of Cell-Based Therapies

WEBINAR SPONSORED BY:

Genotyping during the active study phase of clinical trials is becoming more popular because of lower costs and the availability of high-throughput

microarray platforms that quickly provide accurate results. During oncology clinical trials, genomics data enable better patient stratification,

optimized study results, and well-planned study designs. In this webinar, sponsored by Brooks Life Sciences, brought to you by The Scientist, a panel of

experts will discuss the current state and future direction of genomic analysis in oncology clinical trials.

LAJOS PUSZTAI,MD, DPHIL

Professor of Medicine (Medical Oncology)

Breast Medical Oncology Group

Yale School of Medicine

FRIDAY, OCTOBER 25

2:30 - 4:00 PM EASTERN TIME

WATCH NOW!

http://www.the-scientist.com/steering-clinical-trials

LAURA J. VAN ‘T VEER,PhD

Leader, Breast Oncology Program

Director, Applied Genomics

UCSF Helen Diller Family Comprehensive

Cancer Center

Angela and Shu Kai Chan

Endowed Chair in Cancer Research

TOPICS TO BE COVERED:

• Pros and cons of biomarker-based patient selection
  versus biomarker discovery in clinical trials


• Breast cancer precision medicine: the right drug for the
  right patient at the right time